Developmental adaptation of the mouse cardiovascular system to elastin haploinsufficiency
J. Clin. Invest. Gilles Faury, et al. 112:1419 doi:10.1172/JCI19028 [
Go to this article.]
Figure 4Alteration in MAP after intravenous injection of Ang II or Ang I receptor antagonists. (
a) Maximal change in MAP in response to a bolus dose (1 μg/kg i.v.;
n = 8 for
Eln+/+,
n = 3 for
Eln+/–) of Ang II. (
b) Blood pressure change in response to infusion of saralasin (10 μg/kg;
n = 2 for each phenotype) and candesartan (100 μg/kg;
n = 3 for
Eln+/+,
n = 5 for
Eln+/–). Error bars show SEM. *Significant difference (
P ≤ 0.05,
t test) between treated and control vessels within each genotype.
